Vascarta Completes Phase 1 Trial of VAS-101 (Vasceptor®) for Knee Osteoarthritis

Vascarta Inc., a clinical-stage biopharmaceutical company developing innovative treatments for pain and inflammation, announced the successful completion of its Phase 1 clinical trial evaluating VAS-101 (Vasceptor®), a proprietary curcumin gel for knee osteoarthritis (OA). The trial was conducted at Clinical Research Australia, Perth, under Principal Investigator Dr. Adrian Lopresti, with data publication expected in the coming months.

The 60-patient, randomized, double-blind, placebo-controlled trial assessed VAS-101 applied topically every other day for 28 days. The primary objective was to evaluate its impact on pain in adults with chronic knee OA. Secondary endpoints included safety, tolerability, quality of life, daily function, and analgesic use.

Dr. Lopresti commented:

"Oral curcumin is limited by poor absorption, reducing its therapeutic potential. In this study, VAS-101 applied topically showed promising pain-relieving effects, suggesting that Vascarta’s Vasporta™ transdermal technology can enhance local and systemic delivery for rapid, targeted relief."

About VAS-101

VAS-101 is a patented, highly concentrated curcumin gel formulated using Vascarta's Vasporta™ transdermal delivery platform. The technology is designed to overcome the bioavailability challenges of oral curcumin, enabling effective local and systemic delivery at lower doses. Curcumin’s anti-inflammatory and analgesic properties make it an attractive option for chronic pain management.

Unmet Need in Knee Osteoarthritis

Knee OA affects millions globally. According to the CDC, 21% of U.S. adults were diagnosed with arthritis between 2019–2021, with the knee being the most impacted joint. Existing treatments range from oral medications to invasive interventions such as corticosteroid injections or knee replacement surgery. Non-invasive, effective, and well-tolerated therapies remain an unmet need, particularly for patients who cannot tolerate long-term NSAID use.

Leadership Perspective

"Osteoarthritis is one of the most prevalent and disabling chronic conditions," said Dr. Richard Prince, Vascarta Chairman, CEO & President.

"The completion of this Phase 1 trial is an important milestone for VAS-101 and supports our vision to provide a safer, effective, and non-invasive alternative for millions of patients worldwide."

About Vascarta

Vascarta is a clinical-stage pharmaceutical company focused on topical and transdermal therapeutics for inflammatory conditions, with lead programs in osteoarthritis and sickle cell disease.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!